Navigation Links
New drug treatment extends lives of men with prostate cancer
Date:5/26/2011

AURORA, Colo. (May 25, 2011) - A drug recently approved by the Food & Drug Administration for the treatment of prostate cancer is proving to give some patients the gift of time. A new study shows abiraterone acetate extends the lives of men with the most advanced form of the disease by about four months. The study in the May 26, 2011 issue of the New England Journal of Medicine was co-authored by Thomas W. Flaig, MD, medical oncologist at the University of Colorado Hospital's Tony Grampsas Urologic Oncology Clinic and assistant professor at the University of Colorado School of Medicine.

"Abiraterone acetate is a new, life-extending pill for the treatment of advanced prostate cancer. Unlike the traditional chemotherapy drugs used in these situations, abiraterone is generally very well tolerated," said Flaig.

The multi-center Phase III clinical trial of 1195 participants looked at the effectiveness of treating patients who had received prior chemotherapy with a combination of abiraterone acetate (ZytigaTM ) and prednisone. When this trial was initiated, there were no treatments that clearly prolonged survival in this late phase of prostate cancer. The patients were randomized to receive abiraterone acetate plus prednisone or a placebo plus prednisone each day. Treatment continued until the cancer progressed, there were unfavorable reactions, a new treatment was initiated or the patient withdrew from the trial.

The study shows participants taking abiraterone acetate lived about four months longer than participants taking the placebo. In addition, more patients receiving abiraterone acetate experienced a significant drop in the PSA blood level than those on the placebo.

"The survival benefit observed in this study is especially notable, since this was seen in the most advanced cases of prostate cancer," said Flaig. "Other studies are being done to examine the benefit of using abiraterone acetate earlier in the disease process, where it may be even more effective."

The FDA approved abiraterone acetate at the end of April. The tablet has few side effects but careful medical attention is required to monitor for specific potential side effects including liver blood test changes, low potassium levels, leg swelling and high blood pressure.


'/>"/>

Contact: Erika Matich
erika.matich@ucdenver.edu
720-848-7852
University of Colorado Denver
Source:Eurekalert

Related medicine news :

1. Unique nerve-stimulation treatment proves effective against drug-resistant epilepsy
2. Clinical trials for new Alzheimers disease treatment to be awarded European Commission €6m funding
3. US study shows that tofacitinib is an efficacious treatment for active RA
4. Research suggests that lipofilling may be safe during conservation treatment for breast cancer
5. New study aims to improve long-term treatment for patients with bipolar disorder
6. PET scans predict effectiveness of treatment for multidrug-resistant tuberculosis in HIV patients
7. IUPUI study first to look at early treatment of depression to reduce heart disease risk
8. Mount Sinai researchers discover possible new target for sarcoma treatment and prevention
9. Quicker detection and treatment of severe sepsis
10. Substantial recovery rate with placebo effect in headache treatment
11. Study identifies novel role for a protein that could lead to new treatments for rheumatoid arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2017)... ... July 25, 2017 , ... Centurion Service ... as Regional Account Manager for the Northeast and Florida regions. In this role, ... their obsolete medical assets. , Jennifer joins Centurion with a wealth of knowledge ...
(Date:7/25/2017)... D.C. (PRWEB) , ... July 25, 2017 , ... ... and their clients, today announced it will be exhibiting and providing demos of ... at the Walter E. Washington Convention Center in Washington D.C. from August 3-6, ...
(Date:7/25/2017)... ... July 25, 2017 , ... Dr. Gina ... Negrette has more than a decade of experience in psychiatry, treating clients in ... fighting addictions, eating disorders, psychotic and manic conditions, as well as those who ...
(Date:7/25/2017)... ... ... SignatureCare Emergency Center – South Austin is treating both adult and pediatric ... , The Emergency Room opened early March, making it the first SignatureCare ... things are running smoothly,” said Aaron Braun, SignatureCare Emergency Center’s Chief Medical Officer. “We’re ...
(Date:7/24/2017)... City, MO (PRWEB) , ... July 24, 2017 , ... ... the acclaimed Saint Luke’s Marion Bloch Neuroscience Institute (SLMBNI), part of ... interim basis since 2016. , Cheerag D. Upadhyaya, MD. M.Sc., FAANS joins ...
Breaking Medicine News(10 mins):
(Date:7/17/2017)... Fla. , July 17, 2017  MedX Holdings, ... branded medical testing, strengthening and rehabilitation equipment, today announced ... Machine Program. MedX is considered the gold standard for ... leader in specialized medical strengthening equipment. ... a lease with the physician or practice who prescribe ...
(Date:7/14/2017)... Endo International plc (NASDAQ: ENDP ) will announce its ... its senior management team will host a conference call and webcast ... The dial-in number to access the call is U.S./ ... passcode is 45397076. Please dial in 10 minutes prior to the ... replay of the call will be available from August 8, 2017 ...
(Date:7/13/2017)... July 13, 2017  Centurion Medical Products, a leader in medical ... ® fecal impaction removal device for hospice patient care. ... Centurion Medical Products ... Patient pain management and emotional comfort are ... help alleviate patient pain while preventing unneeded emergency department admission due ...
Breaking Medicine Technology: